BioSpace News Archive

Day One Biopharmaceuticals announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced financial results for the three months ended June 30, 2022 and provided a corporate update.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022.

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the second quarter ended June 30, 2022.

Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2022.

Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/461,354, with formulation and method of use claims around OPNT003, the Company’s investigational treatment for opioid overdose.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2022.